As shown in Fig. 7 and Supplementary Figure 5, we found that maraviroc attenuates colon inflammation in this setting and reduced signs and symptoms of colitis, as well as the inflow of CD45+ cells into the LP. This evidence concerns the gene PTPRC and digestive system neoplasm.